Dr. Kishore Harjai, MD
Claim this profileSt. Louis University
Studies Myocardial Ischemia
Studies Coronary Artery Disease
3 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Kishore Harjai, MD is currently running
PCI vs Medical Management
for Aortic Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.
Recruiting1 award N/A4 criteria
Tendyne Transcatheter Mitral Valve System
for Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Recruiting1 award N/A4 criteria
More about Kishore Harjai, MD
Clinical Trial Related7 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Kishore Harjai, MD has experience with
- Balloon Angioplasty
- Orbital Atherectomy
- Percutaneous Coronary Intervention (PCI)
- Tendyne Mitral Valve System
- MitraClip System
Breakdown of trials Kishore Harjai, MD has run
Myocardial Ischemia
Coronary Artery Disease
Myocardial Infarction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kishore Harjai, MD specialize in?
Kishore Harjai, MD focuses on Myocardial Ischemia and Coronary Artery Disease. In particular, much of their work with Myocardial Ischemia has involved treating patients, or patients who are undergoing treatment.
Is Kishore Harjai, MD currently recruiting for clinical trials?
Yes, Kishore Harjai, MD is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Kishore Harjai, MD has studied deeply?
Yes, Kishore Harjai, MD has studied treatments such as Balloon Angioplasty, Orbital Atherectomy, Percutaneous Coronary Intervention (PCI).
What is the best way to schedule an appointment with Kishore Harjai, MD?
Apply for one of the trials that Kishore Harjai, MD is conducting.
What is the office address of Kishore Harjai, MD?
The office of Kishore Harjai, MD is located at: St. Louis University, Saint Louis, Missouri 63110 United States. This is the address for their practice at the St. Louis University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.